
Opinion|Videos|December 6, 2024
Final Clinical Perspectives: EV+P is the New Standard of Care in Frontline Treatment of UC
Author(s)Thomas Powles MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MD, discusses how according to the ESMO guidelines, enfortumab vedotin plus pembrolizumab (EV+P) has become the new standard of first-line therapy in advanced urothelial carcinoma, and if there are patients who are ineligible for EV+P, alternatives are available such as nivolumab plus cisplatin/gemcitabine or platinum-based chemotherapy followed by maintenance avelumab.
Advertisement
Episodes in this series

Advertisement
Related to this article

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5


